|
UA73965C2
(en)
*
|
1999-12-08 |
2005-10-17 |
Theravance Inc |
b2 ADRENERGIC RECEPTOR ANTAGONISTS
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
TW200510277A
(en)
*
|
2003-05-27 |
2005-03-16 |
Theravance Inc |
Crystalline form of β2-adrenergic receptor agonist
|
|
TW200526547A
(en)
*
|
2003-09-22 |
2005-08-16 |
Theravance Inc |
Amino-substituted ethylamino β2 adrenergic receptor agonists
|
|
TW200531692A
(en)
*
|
2004-01-12 |
2005-10-01 |
Theravance Inc |
Aryl aniline derivatives as β2 adrenergic receptor agonists
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
US7846973B2
(en)
*
|
2004-04-02 |
2010-12-07 |
Theravance, Inc. |
Chemical process and new crystalline form
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
EP1786762A2
(en)
*
|
2004-09-10 |
2007-05-23 |
Theravance, Inc. |
Amidine substituted aryl aniline compounds
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
WO2006051373A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Pfizer Limited |
Compounds for the treatment of diseases
|
|
WO2006066907A1
(en)
*
|
2004-12-21 |
2006-06-29 |
Glaxo Group Limited |
Pharmaceutical formulations
|
|
ES2265276B1
(es)
|
2005-05-20 |
2008-02-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
|
DE102005035891A1
(de)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
SG174054A1
(en)
|
2006-05-04 |
2011-09-29 |
Boehringer Ingelheim Int |
Polymorphs
|
|
CN101868465B
(zh)
|
2007-09-19 |
2013-12-25 |
埃姆比特生物科学公司 |
包含N-(5-叔丁基-异噁唑-3-基)-N’-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2，1-b][1，3]苯并噻唑-2-基]苯基}脲的固体形式、其组合物及其应用
|
|
JP5325517B2
(ja)
*
|
2007-10-12 |
2013-10-23 |
住友化学株式会社 |
ジベンゾオキセピン化合物の精製方法
|
|
JP2009102249A
(ja)
*
|
2007-10-22 |
2009-05-14 |
Sumitomo Chemical Co Ltd |
ジベンゾオキセピン化合物の結晶の製造方法
|
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
KR20110067096A
(ko)
|
2008-09-10 |
2011-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 및 관련 상태를 치료하기 위한 병용 요법
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
EA022310B1
(ru)
|
2008-12-23 |
2015-12-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Солевые формы органического соединения
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
EP2228368A1
(en)
|
2009-03-12 |
2010-09-15 |
Almirall, S.A. |
Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
|
|
WO2011061527A1
(en)
|
2009-11-17 |
2011-05-26 |
Astrazeneca Ab |
Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
|
|
BR112012012641A2
(pt)
|
2009-11-27 |
2020-08-11 |
Boehringer Ingelheim International Gmbh |
TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
|
|
KR101927068B1
(ko)
|
2010-05-05 |
2018-12-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
|
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
|
GB201016912D0
(en)
|
2010-10-07 |
2010-11-24 |
Astrazeneca Ab |
Novel combination
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
EP3517539B1
(en)
|
2011-07-15 |
2022-12-14 |
Boehringer Ingelheim International GmbH |
Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
|
|
EP2578570A1
(en)
|
2011-10-07 |
2013-04-10 |
Almirall, S.A. |
Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
EP2641900A1
(en)
|
2012-03-20 |
2013-09-25 |
Almirall, S.A. |
Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
|
|
JP6285419B2
(ja)
|
2012-05-08 |
2018-02-28 |
ニコックス アフサァルミィクス、 インコーポレイテッドＮｉｃｏｘ Ｏｐｈｔｈａｌｍｉｃｓ， Ｉｎｃ． |
疎水性治療剤の調製物、製造方法およびその使用
|
|
US8765725B2
(en)
|
2012-05-08 |
2014-07-01 |
Aciex Therapeutics, Inc. |
Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
|
|
EP4151218A1
(en)
|
2012-05-14 |
2023-03-22 |
Boehringer Ingelheim International GmbH |
Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
|
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
US9815865B2
(en)
|
2013-01-07 |
2017-11-14 |
Nicox Ophthalmics, Inc. |
Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
|
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｄｐｐ−４阻害薬の医学的使用
|
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
|